Lung Cancer
Volume 45 , Pages S129-S131 , August 2004

Malignant mesothelioma: Medical oncology: standards, new trends, trials—the French experience

References 

  1. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerrin J-C, et al.  Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74:2460–2467
  2. Astoul P, Viallat J-R, Laurent JC, Brandely M, Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest. 1993;103:209–213
  3. Astoul P, Picat-Joossen D, Viallat J-R, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. Cancer. 1998;83:2099–2104
  4. Soulié P, Ruffié P, Trandafir L, Monnet I, Tardivon A, Terrier P, et al.  Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alpha-2a. J. Clin. Oncol. 1996;14:878–885
  5. Trandafir L, Ruffié P, Borel C, Monnet I, Soulié P, Adams D, et al.  Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur. J. Cancer. 1997;33:1900–1902
  6. Rodier JM, Couteau C, Ruffié P, Terrier P, Le Chevalier T, Armand J-P. Phase II study of a monthly combination of cisplatin, mitomycin C and interferon alpha in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 1996;15:390; (Abstract)
  7. Caliandro R, Escudier B, Grall I, Bedin A, Ruffié P. Etude de phase II de chimio-immunotherapie sequentielle de l’association cisplatine (CDDP) i.v., interleukine (IL-2) sous-cutanée, interferon alpha (IFNa) dans le mésotheliome malin diffus de la plèvre. Bull. Cancer. 1998;85:495; (Abstract)
  8. Kasseyet S, Astoul P, Boutin C. Results of a phase II trial combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer. 1999;85:1740–1749
  9. Caliandro R, Boutin C, Perol M, Monnet I, Dabouis G, Guerin JC, et al.  Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma. Lung Cancer. 1997;18(Suppl 1):19; (Abstract)
  10. Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria JC, et al.  Phase I, dose finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol. 2000;18:2293–2300
  11. Fizazi K, Caliandro R, Soulié P, Fandi A, et al.  Combination raltitrexed (Tomudex)-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur. J. Cancer. 2000;36:1514–1521

PII: S0169-5002(04)00184-9

doi: 10.1016/j.lungcan.2004.04.023

Lung Cancer
Volume 45 , Pages S129-S131 , August 2004

Article Tools